Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist compared with oxybutynin in the treatment of patients with overactive bladder
Zinner N1, Tuttle J 2, Marks L 3 1. Medical Director, Western Clinical Research Inc. Los Angeles, USA, 2. Network Trials Inc. , Lexington, USA, 3. Urological Sciences Research Foundation and UCLA Department of Urology, Los Angeles, USA
|
|
Abstract 378
|
|
|
Read By Title:
Scientific Non Discussion Abstract Session 21
|
|
|